- Home
- IVVD vs CVM Comparison
IVVD vs CVM Comparison
Compare IVVD & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- CVM
- Stock Information
- Founded
- IVVD 2020
- CVM 1983
- Country
- IVVD United States
- CVM United States
- Employees
- IVVD N/A
- CVM N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVVD Health Care
- CVM Health Care
- Exchange
- IVVD Nasdaq
- CVM Nasdaq
- Market Cap
- IVVD 63.4M
- CVM 71.2M
- IPO Year
- IVVD 2021
- CVM 1987
- Fundamental
- Price
- IVVD $1.43
- CVM $10.03
- Analyst Decision
- IVVD Strong Buy
- CVM
- Analyst Count
- IVVD 4
- CVM 0
- Target Price
- IVVD $3.64
- CVM N/A
- AVG Volume (30 Days)
- IVVD 15.0M
- CVM 303.9K
- Earning Date
- IVVD 11-13-2025
- CVM 08-14-2025
- Dividend Yield
- IVVD N/A
- CVM N/A
- EPS Growth
- IVVD N/A
- CVM N/A
- EPS
- IVVD N/A
- CVM N/A
- Revenue
- IVVD $46,210,000.00
- CVM N/A
- Revenue This Year
- IVVD $385.94
- CVM N/A
- Revenue Next Year
- IVVD $62.62
- CVM N/A
- P/E Ratio
- IVVD N/A
- CVM N/A
- Revenue Growth
- IVVD 1941.08
- CVM N/A
- 52 Week Low
- IVVD $0.35
- CVM $1.98
- 52 Week High
- IVVD $2.74
- CVM $39.30
- Technical
- Relative Strength Index (RSI)
- IVVD 72.86
- CVM 52.57
- Support Level
- IVVD $0.96
- CVM $9.58
- Resistance Level
- IVVD $1.45
- CVM $12.68
- Average True Range (ATR)
- IVVD 0.19
- CVM 1.30
- MACD
- IVVD 0.05
- CVM -0.28
- Stochastic Oscillator
- IVVD 97.86
- CVM 28.57
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.